NeuroBo Pharmaceuticals announced it received written communication from the U.S. Food and Drug Administration (FDA) that the clinical development program for Gemcabene.
Shares in Gemphire Therapeutics more than doubled after its lead drug gemcabene aced a midstage trial in patients with high triglycerides—setting up a phase 3 program.